An approach to the young hypertensive patient by Mangena, Phetho et al.
CME
36       January 2016, Vol. 106, No. 1
ARTICLE
An approach to the young hypertensive patient
P Mangena,1 MB ChB, FCP (SA); S Saban,2 MB ChB, MFamMed, FCFP (SA); 
K E Hlabyago,3 BSc (Education), MSc, MB ChB, MMed (Family Medicine); B Rayner,1 MB ChB, MMed, FCP (SA), PhD
1  Division of Nephrology and Hypertension, Faculty of Health Sciences, Groote Schuur Hospital and University of Cape Town, South Africa
2  Private Practice, and Division of Family Medicine, School of Public Health and Family Medicine, Faculty of Health Sciences, 
 University of Cape Town, South Africa
3  Department of Family Medicine, Dr George Mukhari Academic Hospital and Sefako Makgatho Health Sciences University, Pretoria, South Africa
Corresponding author: P Mangena (mngphe002@myuct.ac.za)
Hypertension is the leading cause of death worldwide. Globally and locally there has been an increase in hypertension in children, adolescents 
and young adults <40 years of age. In South Africa, the first decade of the millennium saw a doubling of the prevalence rate among adolescents 
and young adults aged 15 ­ 24 years. This increase suggests that an explosion of cerebrovascular disease, cardiovascular disease and chronic 
kidney disease can be expected in the forthcoming decades. A large part of the increased prevalence can be attributed to lifestyle factors such 
as diet and physical inactivity, which lead to overweight and obesity. The majority (>90%) of young patients will have essential or primary 
hypertension, while only a minority (<10%) will have secondary hypertension. We do not recommend an extensive workup for all newly 
diagnosed young hypertensives, as has been the practice in the past. We propose a rational approach that comprises a history to identify risk 
factors, an examination that establishes the presence of target­organ damage and identifies clues suggesting secondary hypertension, and a 
limited set of basic investigations. More specialised tests should be performed only where there is a clinical suspicion that a secondary cause for 
hypertension exists. There have been no randomised clinical trials on the treatment of hypertension in young patients. Expert opinion advises an 
initial emphasis on lifestyle modification. This can comprise a diet with reduced salt and refined carbohydrate intake, an exercise programme and 
management of substance abuse issues. Failure of lifestyle measures or the presence of target­organ damage should prompt the clinician to initiate 
pharmacotherapy. We recommend referral to a specialist practitioner in cases of resistant hypertension, where there is severe target­organ damage 
and when a secondary cause is suspected. 
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Hypertension is a major cause of mortality and 
morbidity globally. It is estimated that >1 billion 
persons worldwide suffer from hyper tension.[1] In the 
2010 Global Burden of Disease study[2] 9 million deaths 
were attributed to hypertension, making it the leading 
cause of death worldwide.
The rate of hypertension has risen over the past few decades to 
reach epidemic proportions among the young[3] (defined in this 
article primarily as adolescents and adults <30 years of age). There is 
a paucity of data on the best way to treat younger patients, and most 
recommendations are extrapolated from evidence in older patients.[4]
This rapid rise is of concern, as it portends an explosion of cardio­
vascular disease, cerebrovascular disease and chronic kidney disease 
in the coming years. Furthermore, due to the traditional approach 
that extensively investigated young hypertensives in search of a 
secondary cause, there are high healthcare costs associated with this 
epidemic.
This article provides a brief overview of hypertension in South 
African (SA) adolescents and young adults. Specific reference is made 
to diagnostic criteria, treatment considerations and referral options.
Epidemiology
Hypertension is defined as a persistent elevation of office blood 
pressure >140/90 mmHg. Approximately a third of the adult SA 
population is hypertensive.[5] Among adolescents and young adults 
(15 ­ 24 years old) the incidence is ~10%.[5] Worryingly, there has 
been a startling increase, with the prevalence approximately doubling 
in this age group within a decade.[3] The reasons include the ‘risk 
transition’, which is characterised by urbanisation, a change in diet 
and lower levels of physical activity.[6] 
There are few data on the long­term outcomes of hypertension 
in the young. However, the available evidence shows that young 
people with hypertension have similar target­organ damage as 
older hypertensives, such as left ventricular hypertrophy (LVH), 
microalbuminuria and carotid intimal thickness. These are associated 
with adverse cardiovascular outcomes.[7,8] 
Pathophysiology
The causes of hypertension in the young can be divided into primary 
and secondary.
Primary hypertension
Primary hypertension (also called essential hypertension) has no 
specific cause, although genetic and environmental factors play an 
important role.[9] More than 90% of young people with hypertension 
have primary hypertension.[7,10] It is often associated with a family 
history of hypertension and frequently accompanied by obesity or 
the metabolic syndrome. International population surveys show an 
increase in obesity in children and adolescents, which parallels an 
increase in the prevalence of hypertension in the same age groups.[11] 
Hypertensive children and adolescents go on to become hypertensive 
adults – a phenomenon known as ‘BP tracking’.[12]
Novel mechanisms implicated in the pathogenesis include low birth 
weight (the Barker­Brenner hypothesis)[13] and hyperuricaemia.[14,15] 
Low­birth­weight and/or small­for­gestational­age infants have a lower 
nephron number at birth (the so­called ‘nephron endowment’), 
which induces physiological changes that lead to hypertension and 
chronic kidney disease later in life.[13] Hyperuricaemia as a cause for 
hypertension in adolescents is an intriguing concept. Experimental 
data indicate that hyperuricaemia invokes renal changes that drive 
hypertension. This ‘hyperuricaemic hypertension’ has in small studies 
been shown to be reversible with urate­lowering therapy, at least in 
the early stages, i.e. soon after diagnosis. (There is not yet enough 
evidence to recommend routine use of urate­lowering therapy in 
young patients.[14,15])
Secondary hypertension
This form of hypertension affects approximately 10% of young 
hypertensives.[7] The probability of secondary hypertension is inverse­
ly proportional to the age of the patient (i.e. higher in a school­going 
child, but lower in a young adult).[7] The importance of identifying 
secondary hypertension lies in the potential for cure with appropriate 
treatment.
The causes of secondary hypertension can be further divided as 
follows:
• renal parenchymal disease (e.g. glomerulonephritis)
• renovascular disease (e.g. renal artery stenosis)
• mineralocorticoid­mediated hypertension (e.g. primary hyper­
aldosteronism)
• catecholamine­mediated hypertension (e.g. phaeochromocytomas)
• medication (e.g. the oral contraceptive pill)
• abuse of cocaine or amphetamines[16]
• coarctation of the aorta
• rarer causes.
Clinical features
Most young patients are asymptomatic and diagnosed during 
screening or when presenting with an unrelated condition. It is 
therefore imperative that opportunistic screening should take place at 
every opportunity. A minority present with a hypertensive emergency 
(such as heart failure, renal failure or malignant hypertension). 
The history should enquire about whether a raised blood 
pressure has been recorded previously and the circumstances in 
which the hypertension was first noted; diabetes mellitus and 
premature cardiovascular disease; use of medication (especially oral 
contraceptives); use of alcohol and tobacco products; and abuse 
of illicit drugs, especially methamphetamines (commonly known 
as ‘tik’), which is associated with severe hypertension and chronic 
kidney disease.[17]
Blood pressure should be recorded using an approved and 
calibrated electronic device or mercury sphygmomanometer. Raised 
blood pressure should be confirmed with multiple readings, and 
consideration should be given to performing out­of­office blood 
pressure measurement (such as home blood pressure or 24­hour 
ambulatory blood pressure monitoring) to exclude ‘white coat’ 
hypertension.[4]
The examination is focused on establishing if there is target­organ 
damage or whether there are features that suggest a secondary cause. 
The presence of target­organ damage should prompt the institution 
of pharmacotherapy and closer follow­up.[4] The clinician should 
look for:
• an elevated body mass index (BMI) and increased waist circum­
ference
• features of insulin resistance (e.g. acanthosis nigricans)
• urinary dipsticks to detect primary renal disease (e.g. glomerulo­
nephritis) or renal damage 
• a pressure overloaded apex in keeping with LVH
• fundoscopy to check for retinal hypertensive changes.
Features that point to a secondary cause include:
• pulse discrepancies (this may suggest a vasculopathy, such as 
Takayasu’s arteritis)
• radiofemoral delay (this suggests coarctation of the aorta)
• abdominal bruits (these are suggestive of renal artery stenosis)
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• flushing, sweating and tachycardia (this may be a clue to the 
presence of a phaeochromocytoma)
• acne, striae, moon facies (these suggest Cushing’s syndrome)
• positive dipsticks for blood and/or protein.
Investigations
We recommend that young hypertensives are not routinely investi­
gated for secondary causes, given the scale of the epidemic and that 
the majority of patients have primary hypertension. Baseline tests that 
should be routinely performed include:[4]
• serum potassium (hypokalaemia may suggest primary hyper aldos­
teronism)
• serum creatinine and determination of estimated glomerular fil­
tration rate
• urine microalbumin­to­creatinine ratio
• fasting blood glucose and lipogram
• 12­lead electrocardiogram (ECG). The clinician should note that the 
ECG is not validated for diagnosis of LVH in individuals <30 years, 
and should be interpreted with caution.[16]
• Where resources allow, an echocardiogram to evaluate for LVH 
may be performed, which is the gold standard for diagnosis.
Specific tests for a secondary cause should only be performed if there 
is a clinical suspicion. These include:
• plasma renin and aldosterone for suspected primary hyper­
aldosteronism
• urinary catecholamines for suspected phaeochromocytoma
• renal sonography for suspected renal disease
• computed tomography angiography of the renal vessels for 
suspected renal artery stenosis
• urine screening for amphetamines and cocaine.
Therapy
Therapy for young hypertensives has not been defined by randomised 
clinical trials and is based on expert opinion. In all instances the main 
focus should be on instituting lifestyle changes.[4] All patients should 
be encouraged to lose weight by eliminating refined carbohydrate 
from their diet, reducing saturated fat intake and undertaking an 
exercise programme or joining an organised sports programme. Fresh 
fruit and vegetables in the diet should be encouraged and salt intake 
must be reduced. Avoidance of junk food is strongly recommended. 
Alcohol use needs to be moderated and all tobacco product use 
discontinued. If substance abuse is detected, the patient should be 
referred for appropriate treatment. 
The role of pharmacotherapy has not been established in young 
people. It should be considered in the following situations: after 
failure of lifestyle therapy, in patients with target­organ damage or 
secondary causes, and in cases of severe hypertension.
Few data are available on the choice of antihypertensive agents. 
It is recommended that medication should be similar to that used 
in adults, as recommended by the South African Hypertension 
Society Practice Guideline on the management of hypertension.[18] 
The three front­line classes of antihypertensive agents are thiazide 
or thiazide­like diuretics, calcium channel blockers, and either an 
angiotensin­converting enzyme (ACE) inhibitor or angiotensin 
receptor blocker. However, it is recommended to reserve the use 
of diuretics in cases of more severe hypertension or where there 
is a compelling indication, such as fluid overload, to avoid the 
long­term metabolic consequences of diuretics, especially the 
predisposition to diabetes mellitus.[4]
When to refer
It is no longer recommended that all young hypertensives be referred 
for specialist evaluation, especially if they are >25 years of age. 
Referral should be considered in the following circumstances:
• blood pressure >180/110 mmHg
• the presence of target­organ damage or complications of hyper­
tension (e.g. heart failure and renal impairment)
• resistant hypertension
• suspected secondary causes.
Conclusion
Hypertension in young people has doubled during the past 10 years and 
has necessitated a re­evaluation of our approach to their evaluation, 
investigation and treatment. There is an urgent need to address 
lifestyle issues that are driving this epidemic. It is also no longer 
recommended that all young hypertensives undergo extensive 
investigation or referral to a specialist. Practical recommendations 
regarding the investigation and treatment of young hypertensives are 
presented.
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